Eric W. Kimble
Director/Board Member at National Psoriasis Foundation, Inc.
Profile
Eric W.
Kimble is on the board of National Psoriasis Foundation, Inc. In his past career Mr. Kimble occupied the position of Product Manager at Merck & Co., Inc. and Vice President-Sales of Cubist Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.), Research Associate at Arthur D.
Little, Inc., Chief Commercial Officer of Entasis Therapeutics Holdings, Inc. and Chief Commercial Officer for Entasis Therapeutics, Inc. (a subsidiary of Entasis Therapeutics Holdings, Inc.), Chief Commercial Officer of Invivyd, Inc. and Marketing Director-US Immunology Franchise at Biogen, Inc.
Eric W.
Kimble received an undergraduate degree from Brown University and an MBA from Harvard Business School.
Eric W. Kimble active positions
Companies | Position | Start |
---|---|---|
National Psoriasis Foundation, Inc.
National Psoriasis Foundation, Inc. Investment Trusts/Mutual FundsMiscellaneous The National Psoriasis Foundation is a non-profit organization that aims to provide assistance to individuals suffering from psoriasis and psoriatic arthritis. The private company is based in Portland, OR. The company strives to help patients get the necessary treatment while also promoting research to find a cure for these conditions. | Director/Board Member | 2010-05-27 |
Former positions of Eric W. Kimble
Companies | Position | End |
---|---|---|
INVIVYD, INC. | Corporate Officer/Principal | 2022-10-12 |
ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 2020-09-03 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 2020-08-31 |
BIOGEN INC. | Sales & Marketing | 2003-12-31 |
MERCK & CO., INC. | Corporate Officer/Principal | 1998-12-31 |
Training of Eric W. Kimble
Brown University | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
BIOGEN INC. | Health Technology |
INVIVYD, INC. | Health Technology |
Private companies | 5 |
---|---|
Cubist Pharmaceuticals LLC
Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Arthur D. Little, Inc.
Arthur D. Little, Inc. Miscellaneous Commercial ServicesCommercial Services Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA. | Commercial Services |
National Psoriasis Foundation, Inc.
National Psoriasis Foundation, Inc. Investment Trusts/Mutual FundsMiscellaneous The National Psoriasis Foundation is a non-profit organization that aims to provide assistance to individuals suffering from psoriasis and psoriatic arthritis. The private company is based in Portland, OR. The company strives to help patients get the necessary treatment while also promoting research to find a cure for these conditions. | Miscellaneous |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Entasis Therapeutics Holdings, Inc.
Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |